To provide a range of innovative tools for accelerating drug development, InnoSer brings people from both scientific and business backgrounds together. With our interview series ‘A day in the life of’, let’s take a glimpse into what it is like to be part of this small...
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
53 million people were affected by Alzheimer’s Disease (AD) in 2013. This was a steep rise from 26.6 million in 2005, and the predictions for 2050 rise further to 106 million cases. Despite the growing demand for AD medicines not only to stabilize but also to treat...
